Heat-sensitive Moxibustion Enhances Immunity in Advanced Non-small Cell Lung Cancer via Th1/Th2 and Treg/Th17 Regulation.

Background: Patients with advanced non-small cell lung cancer (NSCLC) often experience poor clinical outcomes following chemotherapy. Heat-sensitive moxibustion (HSM), a traditional therapeutic intervention, has been reported to improve symptoms and quality of life in patients with cancer. Objective: To evaluate the effect of HSM in patients with advanced NSCLC following chemotherapy. Methods: Between January 2023 and February 2024, patients with advanced NSCLC were enrolled. Eligible patients were randomly assigned to either the chemotherapy (control) group or the chemotherapy plus HSM treatment (HSM) group. Following treatment, the percentages of CD4+ T cell subsets were evaluated, and the serum levels of CD4+ T cells-associated cytokines were measured using enzyme-linked immunosorbent assay (ELISA). The expression levels of CD4+ T cells-related factors were assessed by RT-qPCR and Western blot analysis. The overall response rate (OPR) and disease control rate (DCR), Karnofsky Performance Status (KPS) score, and incidence of adverse events were compared between the two groups. Results: A total of 90 patients with NSCLC were included with 45 patients in each group. The ratio of Th1/Th2 was significantly elevated, whereas the Treg/Th17 ratio was significantly decreased in the HSM group compared with the control group. The HSM group exhibited higher serum levels of IL-2, IL-17A and IFN-γ, and lower levels of IL-4 and IL-10 than the control group. HSM treatment significantly upregulated the expression of T-bet and IL-17A while downregulating GATA3 expression at both the mRNA and protein levels. The HSM group demonstrated superior clinical outcomes, as evidenced by higher KPS score, ORR, DCR, along with a lower incidence of adverse events. Conclusion: HSM may enhance immune function in patients with advanced NSCLC undergoing chemotherapy by modulating the balance of Th1/Th2 and Treg/Th17 cell subsets.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-06-28
DOI
https://doi.org/10.22034/iji.2026.110224.3168
Primary Topic
Acupuncture Treatment Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Heat-sensitive Moxibustion Enhances Immunity in Advanced Non-small Cell Lung Cancer via Th1/Th2 and Treg/Th17 Regulation.

Liqiang Zhang, Xia Li, Haiying Zan, Peichun Li et al.
PubMed
Acupuncture Treatment Research Studies
article

Heat-sensitive Moxibustion Enhances Immunity in Advanced Non-small Cell Lung Cancer via Th1/Th2 and Treg/Th17 Regulation.

Liqiang Zhang, Xia Li, Haiying Zan, Peichun Li, Nan Luo
article en

Abstract

Background: Patients with advanced non-small cell lung cancer (NSCLC) often experience poor clinical outcomes following chemotherapy. Heat-sensitive moxibustion (HSM), a traditional therapeutic intervention, has been reported to improve symptoms and quality of life in patients with cancer. Objective: To evaluate the effect of HSM in patients with advanced NSCLC following chemotherapy. Methods: Between January 2023 and February 2024, patients with advanced NSCLC were enrolled. Eligible patients were randomly assigned to either the chemotherapy (control) group or the chemotherapy plus HSM treatment (HSM) group. Following treatment, the percentages of CD4+ T cell subsets were evaluated, and the serum levels of CD4+ T cells-associated cytokines were measured using enzyme-linked immunosorbent assay (ELISA). The expression levels of CD4+ T cells-related factors were assessed by RT-qPCR and Western blot analysis. The overall response rate (OPR) and disease control rate (DCR), Karnofsky Performance Status (KPS) score, and incidence of adverse events were compared between the two groups. Results: A total of 90 patients with NSCLC were included with 45 patients in each group. The ratio of Th1/Th2 was significantly elevated, whereas the Treg/Th17 ratio was significantly decreased in the HSM group compared with the control group. The HSM group exhibited higher serum levels of IL-2, IL-17A and IFN-γ, and lower levels of IL-4 and IL-10 than the control group. HSM treatment significantly upregulated the expression of T-bet and IL-17A while downregulating GATA3 expression at both the mRNA and protein levels. The HSM group demonstrated superior clinical outcomes, as evidenced by higher KPS score, ORR, DCR, along with a lower incidence of adverse events. Conclusion: HSM may enhance immune function in patients with advanced NSCLC undergoing chemotherapy by modulating the balance of Th1/Th2 and Treg/Th17 cell subsets.

PubMedVol. 23(2)
Weifang Chinese Medicine Hospital (CN)
Openalex Percentile: Top 5%
Acupuncture Treatment Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.